301 related articles for article (PubMed ID: 26386320)
41. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.
Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F
Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
[TBL] [Abstract][Full Text] [Related]
43. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
[TBL] [Abstract][Full Text] [Related]
44. Treatment difficulty with acute GVHD - frequent cause of mortality after allogeneic hematopoietic stem cell transplantation.
Lukas J; Bojtarova E; Mistrik M; Bujdak J; Sopko L; Hatalova A; Martisova M
Bratisl Lek Listy; 2014; 115(2):80-2. PubMed ID: 24601700
[TBL] [Abstract][Full Text] [Related]
45. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
47. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F; Caballero-Velázquez T; López-Villar O; Redondo A; Parody R; Martínez C; Olavarría E; Andreu E; Prósper F; Díez-Campelo M; Regidor C; Villaron E; López-Corral L; Caballero D; Cañizo MC; Pérez-Simon JA
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1580-5. PubMed ID: 24952358
[TBL] [Abstract][Full Text] [Related]
48. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.
Nadeau M; Perreault S; Seropian S; Foss F; Isufi I; Cooper DL
Bone Marrow Transplant; 2016 Feb; 51(2):273-6. PubMed ID: 26479982
[TBL] [Abstract][Full Text] [Related]
49. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
50. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease.
Knop S; Hebart H; Gscheidle H; Holler E; Kolb HJ; Niederwieser D; Einsele H
Bone Marrow Transplant; 2005 Nov; 36(9):831-7. PubMed ID: 16151429
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease.
Nishimoto M; Koh H; Hirose A; Nakamae M; Nakane T; Hayashi Y; Okamura H; Yoshimura T; Koh S; Nanno S; Nakashima Y; Takeshita T; Yamamoto A; Sakai Y; Nishida N; Matsuoka T; Miki Y; Hino M; Nakamae H
Exp Hematol; 2015 Dec; 43(12):995-1000. PubMed ID: 26303639
[TBL] [Abstract][Full Text] [Related]
52. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).
Castilla C; Pérez-Simón JA; Sanchez-Guijo FM; Díez-Campelo M; Ocio E; Pérez-Persona E; López-Villar O; Vazquez L; Caballero D; San Miguel JF
Biol Blood Marrow Transplant; 2006 Sep; 12(9):936-41. PubMed ID: 16920559
[TBL] [Abstract][Full Text] [Related]
53. Intra-arterial steroid-injection therapy for steroid-refractory acute graft-versus-host disease with the evaluation of angiography.
Nakai K; Tajima K; Tanigawa N; Matsumoto N; Zen K; Nomura S; Fujimoto M; Kishimoto Y; Amakawa R; Sawada S; Fukuhara S
Bone Marrow Transplant; 2004 Jun; 33(12):1231-3. PubMed ID: 15094752
[TBL] [Abstract][Full Text] [Related]
54. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients.
Faraci M; Calevo MG; Giardino S; Leoni M; Ricci E; Castagnola E; Lanino E
Biol Blood Marrow Transplant; 2019 Apr; 25(4):743-748. PubMed ID: 30471340
[TBL] [Abstract][Full Text] [Related]
55. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.
Tan Y; Xiao H; Wu D; Luo Y; Lan J; Liu Q; Yu K; Shi J; He J; Zheng W; Lai X; Zhu Y; Du K; Ye Y; Zhao Y; Zheng G; Hu Y; Han X; Zheng Y; Wei G; Cai Z; Huang H
Oncoimmunology; 2017; 6(3):e1277307. PubMed ID: 28405499
[TBL] [Abstract][Full Text] [Related]
56. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
57. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.
Arai S; Margolis J; Zahurak M; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2002; 8(3):155-60. PubMed ID: 11939605
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
[No Abstract] [Full Text] [Related]
59. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
60. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
